Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection

被引:24
|
作者
Scott, Lesley J. [1 ]
机构
[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand
关键词
PLUS LAMIVUDINE; NAIVE ADULTS; RALTEGRAVIR; ELVITEGRAVIR; ADHERENCE; THERAPY;
D O I
10.1007/s40265-019-01247-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The oral once-daily, fixed-dose single-tablet regimen (STR) of dolutegravir/lamivudine (Dovato (R)), combining a second generation integrase single-strand transfer inhibitor (INSTI) and a nucleoside reverse transcriptase inhibitor (NRTI), is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents (> 12 years of age weighing at least 40 kg) with no known or suspected resistance to the INSTI class or lamivudine. In GEMINI trials in antiretroviral therapy (ART)-naive HIV-1-infected adults, treatment with dolutegravir plus lamivudine provided rapid and sustained virological suppression and was noninferior to dolutegravir plus tenofovir disoproxil fumarate/emtricitabine at 48 weeks, irrespective of baseline patient or disease characteristics. Virological suppression was sustained at 96 weeks in these ongoing trials. In patients with HIV-1 with sustained virological suppression on their current tenofovir alafenamide (AF)-based ART regimen (>= 3 drugs), switching to treatment with dolutegravir/lamivudine was noninferior to continuing on a tenofovir AF-based regimen at 48 weeks in the ongoing TANGO trial. No resistance mutations to dolutegravir or lamivudine were detected in patients who met criteria for confirmed virological withdrawal in GEMINI and TANGO trials. Hence, the dolutegravir/lamivudine STR is an effective, generally well tolerated and convenient initial and subsequent ART option for adolescents and adults with HIV-1 infection with no known or suspected resistance to the INSTI class or lamivudine.
引用
收藏
页码:61 / 72
页数:12
相关论文
共 50 条
  • [1] Abacavir/Dolutegravir/Lamivudine Single-Tablet Regimen: A Review of Its Use in HIV-1 Infection
    Sarah L. Greig
    Emma D. Deeks
    Drugs, 2015, 75 : 503 - 514
  • [2] Abacavir/Dolutegravir/Lamivudine Single-Tablet Regimen: A Review of Its Use in HIV-1 Infection (vol 75, pg 503, 2015)
    Greig, Sarah L.
    Deeks, Emma D.
    DRUGS, 2015, 75 (05) : 561 - 561
  • [3] Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients
    Rodriguez-Gonzalez, Carmen Guadalupe
    Chamorro-de-Vega, Esther
    Ortega-Navarro, Cristina
    Alonso, Roberto
    Herranz-Alonso, Ana
    Sanjurjo-Saez, Maria
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (07) : 633 - 643
  • [4] Less is more: A novel single-tablet regimen with two-drugs, dolutegravir/lamivudine
    Sun, Jianjun
    Lu, Hongzhou
    DRUG DISCOVERIES AND THERAPEUTICS, 2021, 15 (04) : 225 - 226
  • [5] Dolutegravir plus lamivudine for the treatment of HIV-1 infection
    Ciccullo, Arturo
    Baldin, Gianmaria
    Borghetti, Alberto
    Di Giambenedetto, Simona
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2020, 18 (04) : 279 - 292
  • [6] Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (Stribild®): A Review of Its Use in the Management of HIV-1 Infection in Adults
    Caroline M. Perry
    Drugs, 2014, 74 : 75 - 97
  • [7] Dolutegravir plus Abacavir-Lamivudine for the Treatment of HIV-1 Infection
    Walmsley, Sharon L.
    Antela, Antonio
    Clumeck, Nathan
    Duiculescu, Dan
    Eberhard, Andrea
    Gutierrez, Felix
    Hocqueloux, Laurent
    Maggiolo, Franco
    Sandkovsky, Uriel
    Granier, Catherine
    Pappa, Keith
    Wynne, Brian
    Min, Sherene
    Nichols, Garrett
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (19) : 1807 - 1818
  • [8] Single-Tablet Regimens in HIV Therapy
    Astuti N.
    Maggiolo F.
    Infectious Diseases and Therapy, 2014, 3 (1) : 1 - 17
  • [9] Single-Tablet Regimens for the Treatment of HIV-I Infection
    Sebaaly, Jamielynn C.
    Kelley, Denise
    ANNALS OF PHARMACOTHERAPY, 2017, 51 (04) : 332 - 344
  • [10] Safety and Efficacy of Coformulated Efavirenz/Emtricitabine/Tenofovir Single-Tablet Regimen in Treatment-Naive Patients Infected with HIV-1
    Gallien, Sebastien
    Flandre, Philippe
    Nga Nguyen
    De Castro, Nathalie
    Molina, Jean-Michel
    Delaugerre, Constance
    JOURNAL OF MEDICAL VIROLOGY, 2015, 87 (02) : 187 - 191